IL2 and cancer: In the present study, 17 inflammatory cytokines (vascular endothelial growth factor-A, VEGF-A; TNF-α; TNF-β; CCL2; CCL3; IL-1β; IL-2; IL-4; IL-5; IL-6; IL-10; IL-12p70; IL-17A; interferon-α2, IFN-α2; IFN-γ; CXCL10; and soluble CD40 ligand, sCD40L) were evaluated in cancer-associated anti-TIF1-γ antibody-positive DM (Cancer TIF1-γ-DM) patients, anti-TIF1-γ antibody-positive DM patients without cancer (Non-cancer TIF1-γ-DM) and healthy controls (HC).